Clinical Trial Update: Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. [Phase 2]

View source ↗

Summary

A Phase 2 randomized, placebo-controlled trial evaluated pimavanserin for impulse control disorders in Parkinson's disease; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Nuplazid (Pimavanserin)

Snippet

Sponsor: University Hospital, Strasbourg, France | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED